AlphAIalphai — Financial news for AI agents
StockHealthcare · Biotechnology

$ARVN

ARVINAS, INC.

Price · $ARVNvia TradingView
AI sentiment · 7d0 articles

No enriched coverage for $ARVN in the last 7 days.

Insider · 30dFeed →

No SEC Form 4 filings for $ARVN in the last 30 days.

Top stories · $ARVNMore →
MAY 13·Simply Wall StreetLow

Pfizer PROTAC Licensing Deal With Rigel Adds Royalties To Valuation Story

Pfizer and Arvinas have licensed global development and commercialization rights for VEPPANU, an FDA-approved oral PROTAC for breast cancer, to Rigel Pharmaceuticals. This deal allows Pfizer and Arvinas to receive royalties and milestone payments, shifting VEPPANU from a fully owned commercial effort to a royalty stream for Pfizer. The agreement enables Pfizer to reallocate resources to its broader oncology and PROTAC pipelines, introducing another potential source of future revenue for investors to track.

MAY 12·Stock Titan

Arvinas (NASDAQ: ARVN) gains first PROTAC FDA nod as Q1 2026 swings to loss

Arvinas reported a significant milestone with FDA approval of VEPPANU (vepdegestrant), the first-ever PROTAC protein degrader, for ESR1-mutated ER+/HER2- advanced or metastatic breast cancer. Despite this approval, the company experienced a sharp revenue decline to $15.6 million from $188.8 million in the prior year and swung to a net loss of $57.6 million in Q1 2026. Arvinas maintains a strong cash position of $614.9 million, projected to fund operations into the second half of 2028, and continues to advance a broad PROTAC pipeline.

MAY 4·Business Wire

Guardant Health Receives FDA Approval for Guardant360® CDx as a Companion Diagnostic for Arvinas and Pfizer’s VEPPANU (vepdegestrant) for Patients with ER+/HER2- Advanced Breast Cancer with ESR1 Mutations

Guardant Health announced FDA approval for its Guardant360® CDx liquid biopsy as a companion diagnostic for VEPPANU (vepdegestrant), a treatment from Arvinas and Pfizer. This approval allows for the non-invasive identification of ER+/HER2- advanced breast cancer patients with ESR1 mutations who are eligible for VEPPANU. It marks Guardant's third ESR1 companion diagnostic approval and the 26th CDx indication for the Guardant360 CDx platform.

News on $ARVN

All news →